CN105944083A - Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent - Google Patents

Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent Download PDF

Info

Publication number
CN105944083A
CN105944083A CN201610287019.8A CN201610287019A CN105944083A CN 105944083 A CN105944083 A CN 105944083A CN 201610287019 A CN201610287019 A CN 201610287019A CN 105944083 A CN105944083 A CN 105944083A
Authority
CN
China
Prior art keywords
parts
nursing agent
fibromyalgia syndrome
compound recipe
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610287019.8A
Other languages
Chinese (zh)
Inventor
董桂芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610287019.8A priority Critical patent/CN105944083A/en
Publication of CN105944083A publication Critical patent/CN105944083A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a compound nursing agent for treating fibromyalgia syndrome and a preparation method of the compound nursing agent. The compound nursing agent consists of the following ingredients: cyclobenzaprine, amitriptyline, paroxetine, baclofen, propantheline, S-adenosylmethionine, nardosinone, celecoxib, lornoxicam, a basic fibroblast growth factor, methycobal, tryptophan, maltodextrin and casein phosphopeptides. The compound nursing agent disclosed by the invention has functions of diminishing inflammation and relieving pain, soothing liver and relieving depression, dispelling wind and eliminating dampness, clearing and activating channels and collaterals, relieving spasms and improving patients' sleep; and based upon clinical verification, the compound nursing agent is relatively high in cure rate on the fibromyalgia syndrome, good in treatment effect, remarkable in curative effect, low in toxic and side effects and free from clinical adverse reactions, and the compound nursing agent has good values and prospects of clinical popularization and application.

Description

A kind of for compound recipe nursing agent treating fibromyalgia syndrome and preparation method thereof
Technical field
The present invention relates to internal medicine nursing medication field, be specifically related to a kind of for treating answering of fibromyalgia syndrome Side's nursing agent and preparation method thereof.
Background technology
Fibromyalgia syndrome (fibromyalgia syndrome, FS) is a kind of nonarticular rheumatism, clinical table It is now musculoskeletal system many places pain and a deadlock, and has pressure pain point at privileged sites.Fibromyalgia syndrome can Being secondary to wound, various rheumatisms, such as osteoarthritis (osteoarthritis, OA), rheumatoid arthritis (rheumatoid arthritis, RA) and various non-rheumatism (such as hypothyroidism, malignant tumor) etc..This Fibrid muscle pain syndrome is referred to as secondary fibromyalgia syndrome (secondary fibromyalgia Syndromen), as without other illness, the most referred to as primary fibromyalgia syndrome (primary fibromyagia syndrome)。
It is mainly characterized by chronic widely, symmetrical musculoskeletal pain, may often be such that the muscle skeleton pain disabled Pain is with unable, with the pressure pain point that multiple symmetry are widely distributed.Can and whole body fatigue stiff with morning, anxiety, Mental symptom, sleep disorder or chronic insomnia, the nocturnal myoclonus such as melancholy, frightened, grind one's teeth in sleep, morning is stiff, occipitalia Jumping pain, feel dizzy, cognitive defect and of short duration amnesia etc..It addition, also have feeling of numbness, twinge Sense, brothers' paraesthesia, gastrointestinal symptoms and bladder disorders are the most common, have a strong impact on the quality of life of patient.FMS Occur at each age level, but 25～the age bracket of 45 years old, the sickness rate of women is seven times of male. FMS can cause individual quality of life and somatic function by heavy damage, and its degree can be closed with rheumatic Joint inflammation is compared.
Fibromyalgia syndrome is a kind of idiopathic disease, and its Pathophysiology is failed to understand so far, the therefore treatment to it Method is also few, and current treatment is directed generally to improve sleep state, lowers the sensitivity of pain sensation sensory receptor, Improve muscle blood flow etc..
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of compound recipe nursing agent for treating fibromyalgia syndrome And preparation method thereof.
A kind of compound recipe nursing agent for treating fibromyalgia syndrome, including the composition of following weight portion: amine benzene Cycloheptene 16～32 parts, amitriptyline 12～23 parts, paroxetine 10～19 parts, baclofen 8～14 parts, general Lu Benxin 7.5～13.5 parts, S-adenosylmethionine 6～12 parts, the glycosides new ketone 4 of pine～11 parts, celecoxib 2～9 Part, lornoxicam 1～5 parts, basic fibroblast growth factor 0.5～1.5 parts, cobinamide 0.1～0.7 part, Tryptophan 18～23 parts, maltodextrin 24～56 parts, phosphopeptide caseinate 34～56 parts.
Further, described amitriptyline is the derivant of dibenzocycloheptene, is to pass through micro passage reaction It is synthesized.Micro passage reaction is that multistep reaction continuous feed in the case of need not separate is produced Thing, not only greatly simplifies operating procedure, saves time and personnel；And improve product quality and life Produce cost.
Further, the described new ketone of glycosides pine is to be extracted by the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos Batal A kind of flavone compound gone out, concrete extraction process is with the dry rhizome of Radix Et Rhizoma Nardostachyos as raw material, dry, pulverize, It is subsequently adding the mixed enzyme enzymolysis of cellulase and pectase, then with ultrasonic extraction 2～3 times, collects ultrasonic Extracting solution and medicinal residues, and medicinal residues distilled water decocting in water again is extracted, collect aqueous extract, merge twice extraction Liquid, is subsequently adding petroleum ether and with ultrasonic extraction, finally uses column chromatography, and collects eluent, concentrates, It is dried, obtains nardosinone；It has calmness, epilepsy, antidepressant, rush nerve growth, improves cognitive energy Power, protecting myocardial cell, blood pressure lowering, the antibacterial and multiple pharmacologically active such as malaria, antitumor.
Another technical scheme of the present invention is: provide a kind of compound recipe nursing for treating fibromyalgia syndrome The preparation method of agent, detailed process is: by described proportioning by prohe tatriene, amitriptyline, paroxetine, The new ketone of baclofen, probanthine, S-adenosylmethionine, glycosides pine, celecoxib, lornoxicam, alkalescence become Fibroblast growth factor, cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate mix, and are subsequently adding The antioxidant of 0.1～0.3 part, the filler of 245～324 parts, the disintegrating agent of 2～4 parts, the lubricant of 3～6 parts, Being placed in blender stirring 20～30min, rotating speed is 400～500r/min, obtains described compound recipe nursing agent.
Further, described compound recipe nursing agent is made sheet by pelletize, tabletting, 10～15 DEG C of low temperature sterilizations Agent.
Further, described antioxidant is: plant polyphenol or tocopherol, and antioxidant can protect medicine Go bad from oxidative damage, and there is in human body alimentary canal antioxidation, prevent digestive tract generation oxygen Change damage, it is ensured that medicine at utmost plays drug effect.
Further, described filler is: pregelatinized Starch, and pregelatinized Starch good fluidity has bonding concurrently And dilution function, and compressibility is good, can increase the mechanical strength of tablet, reduces the breakage rate adding man-hour, and can Strengthen the stability of medicine preferentially to combine moisture, do not react with principal agent.
Further, described disintegrating agent is: crospolyvinylpyrrolidone；Crospolyvinylpyrrolidone has There are hygroscopicity, easy mobility, the strongest expansion character and the complexing power with multiclass material, in medical industry It is mainly used as the disintegrating agent of tablet, and crospolyvinylpyrrolidone also can improve capillary activity and hydration energy Power.
Further, described wetting agent is: magnesium stearate, and magnesium stearate has good mobility, makes pressure Can feed smoothly and slice during sheet, and reduce sticking and reducing and rub between granule and granule, tablet and nib wall Wiping power, makes unilateral smooth and beautiful appearance.
Compared with prior art, beneficial effects of the present invention is embodied in: the compound recipe nursing agent of the present invention has antiinflammatory Analgesia, dispersing the stagnated live-QI to relieve the stagnation of QI, expelling wind and removing dampness, dredge the meridian passage, solution spasm, the effect of patient sleeps improved, wherein amine The new ketone of phenyl ring heptene, amitriptyline, paroxetine, glycosides pine has antidepressant, improves patient sleeps, releases flesh The effect of spasm；Baclofen, probanthine, S-adenosylmethionine, basic fibroblast growth factor are mainly done Disturb excitatory neurotransmitter release, the conduction between suppression spinal cord synapse, dredge the meridian passage, trophic nerve；Plug carrys out former times Cloth, lornoxicam anti-inflammatory and antalgic；Main cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate master To prevent patient from side reaction occurring during taking medicine as nutrient substance in conjunction with other drug composition, and The immunity of patient, beneficially patient can be improved recover rapidly.And the present invention is according to clinical verification to fibromyalgia Syndrome cure rate is higher, and good absorbing effect is evident in efficacy, and toxic and side effects is little, without clinical adverse, tool There are good clinic popularization and application values and prospect.
Detailed description of the invention
Embodiment 1: the present embodiment prepares the sheet of a kind of compound recipe nursing agent for treating fibromyalgia syndrome Agent, including the composition of following weight portion: prohe tatriene 16 parts, amitriptyline 12 parts, paroxetine 10 Part, the new ketone 4 parts of baclofen 8 parts, probanthine 7.5 parts, S-adenosylmethionine 6 parts, glycosides pine, plug come Former times cloth 2 parts, lornoxicam 1 part, basic fibroblast growth factor 0.5 part, cobinamide 0.1 part, color ammonia Acid 18 parts, maltodextrin 24 parts, phosphopeptide caseinate 34 parts.
Wherein, described amitriptyline is the derivant of dibenzocycloheptene, is to be reacted by micro passage reaction Synthesis.Micro passage reaction is that multistep reaction continuous feed in the case of need not separate obtains product, no But greatly simplifie operating procedure, save time and personnel；And improve product quality and production cost.
Wherein, the described new ketone of glycosides pine is to be extracted by the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos Batal A kind of flavone compound, concrete extraction process is with the dry rhizome of Radix Et Rhizoma Nardostachyos as raw material, dry, pulverize, so Rear addition cellulase and the mixed enzyme enzymolysis of pectase, then use ultrasonic extraction 2 times, collects supersound extraction Liquid, and medicinal residues distilled water decocting in water again is extracted, collect aqueous extract, merge twice extracting solution, then add Enter petroleum ether and with ultrasonic extraction, finally use column chromatography, collect eluent, concentrate, be dried, obtain Nardosinone；It has calmness, epilepsy, antidepressant, rush nerve growth, improves cognitive competence, the protection heart Myocyte, blood pressure lowering, the antibacterial and multiple pharmacologically active such as malaria, antitumor.
The preparation side of a kind of compound recipe nursing agent tablet for treating fibromyalgia syndrome prepared by the present embodiment Method, detailed process is: by described proportioning by prohe tatriene, amitriptyline, paroxetine, baclofen, general The new ketone of Lu Benxin, S-adenosylmethionine, glycosides pine, celecoxib, lornoxicam, basic fibroblast growth because of Son, cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate mix, and are subsequently adding 0.1 part anti- Oxidant, the filler of 245 parts, the disintegrating agent of 2 parts, the lubricant of 3 parts, be placed in blender stirring 20min, Rotating speed is 400r/min, obtains described compound recipe nursing agent, then by pelletize, tabletting, 10 DEG C of low temperature sterilizations Make tablet, every 0.5g.
Wherein, described antioxidant is: plant polyphenol, and antioxidant can protect the drug against oxidative damage And go bad, and there is in human body alimentary canal antioxidation, prevent digestive tract generation oxidative damage, it is ensured that Medicine at utmost plays drug effect.
Wherein, described filler is: pregelatinized Starch, pregelatinized Starch good fluidity, has bonding concurrently with dilute Release function, and compressibility is good, the mechanical strength of tablet can be increased, reduce the breakage rate adding man-hour, Ke Yiyou First combine moisture and strengthen the stability of medicine, do not react with principal agent.
Wherein, described disintegrating agent is: crospolyvinylpyrrolidone；Crospolyvinylpyrrolidone has suction Moist, easy mobility, the strongest expansion character and the complexing power with multiclass material, main in medical industry As the disintegrating agent of tablet, and crospolyvinylpyrrolidone also can improve capillary activity and hydratability.
Wherein, described wetting agent is: magnesium stearate, and magnesium stearate has good mobility, when making tabletting Can feed smoothly and slice, and reduce sticking and reduce frictional force between granule and granule, tablet and nib wall, Make unilateral smooth and beautiful appearance.
Usage and dosage: three times a day, each 2, one after each meal.
Embodiment 2: the present embodiment prepares the sheet of a kind of compound recipe nursing agent for treating fibromyalgia syndrome Agent, including the composition of following weight portion: prohe tatriene 24 parts, amitriptyline 17.5 parts, paroxetine 14.5 Part, the new ketone 7.5 parts of baclofen 11 parts, probanthine 10.5 parts, S-adenosylmethionine 9 parts, glycosides pine, Celecoxib 5.5 parts, lornoxicam 3 parts, basic fibroblast growth factor 1 part, cobinamide 0.4 part, Tryptophan 20.5 parts, maltodextrin 40 parts, phosphopeptide caseinate 45 parts.
Wherein, described amitriptyline is the derivant of dibenzocycloheptene, is to be reacted by micro passage reaction Synthesis.Micro passage reaction is that multistep reaction continuous feed in the case of need not separate obtains product, no But greatly simplifie operating procedure, save time and personnel；And improve product quality and production cost.
Wherein, the described new ketone of glycosides pine is to be extracted by the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos Batal A kind of flavone compound, concrete extraction process is with the dry rhizome of Radix Et Rhizoma Nardostachyos as raw material, dry, pulverize, so Rear addition cellulase and the mixed enzyme enzymolysis of pectase, then use ultrasonic extraction 2 times, collects supersound extraction Liquid and medicinal residues, and medicinal residues distilled water decocting in water again is extracted, collect aqueous extract, merge twice extracting solution, It is subsequently adding petroleum ether and with ultrasonic extraction, finally uses column chromatography, collect eluent, concentrate, be dried, Obtain nardosinone；It has calmness, epilepsy, antidepressant, rush nerve growth, improves cognitive competence, guarantor Protect myocardial cell, blood pressure lowering, the antibacterial and multiple pharmacologically active such as malaria, antitumor.
The preparation side of a kind of compound recipe nursing agent tablet for treating fibromyalgia syndrome prepared by the present embodiment Method, detailed process is: by described proportioning by prohe tatriene, amitriptyline, paroxetine, baclofen, general The new ketone of Lu Benxin, S-adenosylmethionine, glycosides pine, celecoxib, lornoxicam, basic fibroblast growth because of Son, cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate mix, and are subsequently adding 0.2 part anti- Oxidant, the filler of 284.5 parts, the disintegrating agent of 3 parts, the lubricant of 4.5 parts, be placed in blender stirring 25min, rotating speed is 450r/min, obtains described compound recipe nursing agent, then by pelletize, tabletting, 12.5 DEG C Low temperature sterilization makes tablet, every 0.5g.
Wherein, described antioxidant is: plant polyphenol, and antioxidant can protect the drug against oxidative damage And go bad, and there is in human body alimentary canal antioxidation, prevent digestive tract generation oxidative damage, it is ensured that Medicine at utmost plays drug effect.
Wherein, described filler is: pregelatinized Starch, pregelatinized Starch good fluidity, has bonding concurrently with dilute Release function, and compressibility is good, the mechanical strength of tablet can be increased, reduce the breakage rate adding man-hour, Ke Yiyou First combine moisture and strengthen the stability of medicine, do not react with principal agent.
Wherein, described disintegrating agent is: crospolyvinylpyrrolidone；Crospolyvinylpyrrolidone has suction Moist, easy mobility, the strongest expansion character and the complexing power with multiclass material, main in medical industry As the disintegrating agent of tablet, and crospolyvinylpyrrolidone also can improve capillary activity and hydratability.
Wherein, described wetting agent is: magnesium stearate, and magnesium stearate has good mobility, when making tabletting Can feed smoothly and slice, and reduce sticking and reduce frictional force between granule and granule, tablet and nib wall, Make unilateral smooth and beautiful appearance.
Usage and dosage: three times a day, each 2, one after each meal.
Embodiment 3: the present embodiment prepares the sheet of a kind of compound recipe nursing agent for treating fibromyalgia syndrome Agent, including the composition of following weight portion: prohe tatriene 32 parts, amitriptyline 23 parts, paroxetine 19 Part, the new ketone 11 parts of baclofen 14 parts, probanthine 13.5 parts, S-adenosylmethionine 12 parts, glycosides pine, Celecoxib 9 parts, lornoxicam 5 parts, basic fibroblast growth factor 1.5 parts, cobinamide 0.7 part, Tryptophan 23 parts, maltodextrin 56 parts, phosphopeptide caseinate 56 parts.
Wherein, described amitriptyline is the derivant of dibenzocycloheptene, is to be reacted by micro passage reaction Synthesis.Micro passage reaction is that multistep reaction continuous feed in the case of need not separate obtains product, no But greatly simplifie operating procedure, save time and personnel；And improve product quality and production cost.
Wherein, the described new ketone of glycosides pine is to be extracted by the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos Batal A kind of flavone compound, concrete extraction process is with the dry rhizome of Radix Et Rhizoma Nardostachyos as raw material, dry, pulverize, so Rear addition cellulase and the mixed enzyme enzymolysis of pectase, then use ultrasonic extraction 3 times, collects supersound extraction Liquid and medicinal residues, and medicinal residues distilled water decocting in water again is extracted, collect aqueous extract, merge twice extracting solution, It is subsequently adding petroleum ether and with ultrasonic extraction, finally uses column chromatography, collect eluent, concentrate, be dried, Obtain nardosinone；It has calmness, epilepsy, antidepressant, rush nerve growth, improves cognitive competence, guarantor Protect myocardial cell, blood pressure lowering, the antibacterial and multiple pharmacologically active such as malaria, antitumor.
The preparation side of a kind of compound recipe nursing agent tablet for treating fibromyalgia syndrome prepared by the present embodiment Method, detailed process is: by described proportioning by prohe tatriene, amitriptyline, paroxetine, baclofen, general The new ketone of Lu Benxin, S-adenosylmethionine, glycosides pine, celecoxib, lornoxicam, basic fibroblast growth because of Son, cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate mix, and are subsequently adding 0.3 part anti- Oxidant, the filler of 324 parts, the disintegrating agent of 4 parts, the lubricant of 6 parts, be placed in blender stirring 30min, Rotating speed is 500r/min, obtains described compound recipe nursing agent, then by pelletize, tabletting, 15 DEG C of low temperature sterilizations Make tablet, every 0.5g.
Wherein, described antioxidant is: tocopherol, antioxidant can protect the drug against oxidative damage and Rotten, and there is in human body alimentary canal antioxidation, prevent digestive tract generation oxidative damage, it is ensured that medicine Product at utmost play drug effect.
Wherein, described filler is: pregelatinized Starch, pregelatinized Starch good fluidity, has bonding concurrently with dilute Release function, and compressibility is good, the mechanical strength of tablet can be increased, reduce the breakage rate adding man-hour, Ke Yiyou First combine moisture and strengthen the stability of medicine, do not react with principal agent.
Wherein, described disintegrating agent is: crospolyvinylpyrrolidone；Crospolyvinylpyrrolidone has suction Moist, easy mobility, the strongest expansion character and the complexing power with multiclass material, main in medical industry As the disintegrating agent of tablet, and crospolyvinylpyrrolidone also can improve capillary activity and hydratability.
Wherein, described wetting agent is: magnesium stearate, and magnesium stearate has good mobility, when making tabletting Can feed smoothly and slice, and reduce sticking and reduce frictional force between granule and granule, tablet and nib wall, Make unilateral smooth and beautiful appearance.
Usage and dosage: three times a day, each 2, one after each meal.
Present invention application in fibromyalgia syndrome:
One. animal toxicity test:
1. animal selects and is administered: choose the mice 60 of health, then by mice at the environment of subzero 20 DEG C Middle raising one day, then raises one day in the environment of 20 DEG C, and cold and heat succeed each other raising one month, promotes mice Have the phenomenon of muscular spasm, tic of the limbs, then mice is randomly divided into 4 groups, often group 15, respectively It is designated as A group, B group, C group, D group.Then ABC group takes the tablet of the embodiment of the present invention 1～3 preparation, Dose is taken by the amount of embodiment requirement；D group takes the embodiment of the present invention 2 by 4 times of embodiment requirement dose The tablet of preparation.Each group gastric infusion respectively, three times a day, successive administration 10 days.
2. test data statistics and result: after off-test, the muscular spasm situation of tri-groups of mices of ABC disappears, and takes out Phenomenon of jerking no longer occurs, each group mice activity increases, and then dissects D group mice, and mice has no any device Official is excessive and organ injury occur due to dose, therefore, the compound preparation of the present invention is safe and effective, and poison is secondary Act on little.
Two. clinical treatment is verified
1, case selection: select the fibromyalgia syndrome patient 80 example clinical observation that certain hospital makes a definite diagnosis, patient Age 21～64 years old, 39.5 years old mean age, patient is randomly divided into four groups, often organizes 20 people, Qi Zhongzhi Treatment group has 3 groups, matched group 1 group, and patient's qualifications and record of service are basically identical, without significant difference, have comparability.
2, Therapeutic Method: treatment group patient takes the tablet of the embodiment of the present invention 1～3 preparation respectively, and dose is pressed The dose that embodiment specifies；Matched group take sell on the market of equivalent for treating fibromyalgia syndrome Medicine, three times a day, takes medicine 20 days continuously.
3, observation index
Use VAS scale to judge the pain degree (0～10.0 as painless, and 10 is the most bitterly) of muscle, observe simultaneously Patient muscle's pain, dysfunction and sleep state, carry out efficacy evaluation after 3 courses for the treatment of.
4, efficacy determination
(1) cure: the clinical symptoms such as myalgia, whole body tenderness, sleep disorder, fatigue and anxiety disappear substantially Losing, physical recovery is healthy, does not affect orthobiosis.
(2) taking a turn for the better: the symptoms such as myalgia, whole body tenderness are substantially alleviated, pain substantially alleviates, sleep disorder, The clinical symptoms such as fatigue and anxiety substantially alleviate.
(3) invalid: symptom is with treating front no significant difference.
5. therapeutic outcome: before and after each group patient treatment outcome and treatment, pain VAS is measured and is compared as follows table:
Group Cure Take a turn for the better Invalid Effective percentage/% VAS before treatment VAS after treatment
Embodiment 1 16 2 2 90 10 7
Embodiment 2 18 1 1 95 10 5
Embodiment 3 17 1 2 90 10 6
Matched group 15 1 4 80 10 8
6. conclusion: from above-mentioned clinical treatment case, compound recipe nursing agent prepared by the present invention has good clinic Effect, its effective percentage reaches 90%, and relatively matched group is high, can effectively treat fibromyalgia syndrome, and curative effect shows Writing, side effect is little.
Although the present invention being described and illustrated with reference to its specific embodiments, but those skilled in the art will appreciate that Arrive, without departing from the spirit and scope of the present invention it can be variously modified, revise and replace. Such as, due to the change of responding ability of the people of treated particular condition, beyond preferred dose as explained above Effective dose may be suitable for.Similarly, it was observed that pharmacology respond may basis and rely on selected given activity Compound or whether there is pharmaceutical carrier and preparation type and mode of administration used and become, according to the mesh of the present invention And practice be contemplated in result this kind of expection change or difference.Therefore, the invention is intended to only by following patent The scope required limits and these claim should be explained in rational degree as broadly as possible.

Claims (9)

1. the compound recipe nursing agent being used for treating fibromyalgia syndrome, it is characterised in that described compound recipe protects Reason agent includes the composition of following weight portion: prohe tatriene 16～32 parts, amitriptyline 12～23 parts, Paro west Spit of fland 10～19 parts, baclofen 8～14 parts, probanthine 7.5～13.5 parts, S-adenosylmethionine 6～12 parts, The new ketone 4 of glycosides pine～11 parts, celecoxib 2～9 parts, lornoxicam 1～5 parts, basic fibroblast growth factor 0.5～1.5 Part, cobinamide 0.1～0.7 part, tryptophan 18～23 parts, maltodextrin 24～56 parts, casein phosphoric acid Peptide 34～56 parts.
A kind of compound recipe nursing agent for treating fibromyalgia syndrome, its feature Being, described amitriptyline is the derivant of dibenzocycloheptene, is to be synthesized by micro passage reaction 's.
A kind of compound recipe nursing agent for treating fibromyalgia syndrome, its feature Being, the described new ketone of glycosides pine is the one extracted by the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos Batal Flavone compound.
A kind of compound recipe nursing agent for treating fibromyalgia syndrome, its feature Being, preparation method is: by described proportioning by prohe tatriene, amitriptyline, paroxetine, baclofen, Probanthine, S-adenosylmethionine, glycosides pine new ketone, celecoxib, lornoxicam, basic fibroblast growth The factor, cobinamide, tryptophan, maltodextrin, phosphopeptide caseinate mix, and are subsequently adding 0.1～0.3 The antioxidant of part, the filler of 245～324 parts, the disintegrating agent of 2～4 parts, the lubricant of 3～6 parts, be placed in Stirring 20～30min in blender, rotating speed is 400～500r/min, obtains described compound recipe nursing agent.
A kind of preparation side of the compound recipe nursing agent for treating fibromyalgia syndrome Method, it is characterised in that described compound recipe nursing agent is made by pelletize, tabletting, 10～15 DEG C of low temperature sterilizations Tablet.
A kind of preparation side of the compound recipe nursing agent for treating fibromyalgia syndrome Method, it is characterised in that described antioxidant is: plant polyphenol or tocopherol.
A kind of preparation side of the compound recipe nursing agent for treating fibromyalgia syndrome Method, it is characterised in that described filler is: pregelatinized Starch.
A kind of preparation side of the compound recipe nursing agent for treating fibromyalgia syndrome Method, it is characterised in that described disintegrating agent is: crospolyvinylpyrrolidone.
A kind of preparation side of the compound recipe nursing agent for treating fibromyalgia syndrome Method, it is characterised in that described wetting agent is: magnesium stearate.
CN201610287019.8A 2016-05-03 2016-05-03 Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent Pending CN105944083A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610287019.8A CN105944083A (en) 2016-05-03 2016-05-03 Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610287019.8A CN105944083A (en) 2016-05-03 2016-05-03 Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent

Publications (1)

Publication Number Publication Date
CN105944083A true CN105944083A (en) 2016-09-21

Family

ID=56913408

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610287019.8A Pending CN105944083A (en) 2016-05-03 2016-05-03 Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent

Country Status (1)

Country Link
CN (1) CN105944083A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678585A (en) * 2002-06-28 2005-10-05 欧洲凯尔特公司 Therapeutic agents useful for treating pain
CN101484152A (en) * 2006-06-08 2009-07-15 舒沃茨药物股份公司 Therapeutic combination for painful medical conditions
CN101657193A (en) * 2007-03-09 2010-02-24 切尔西治疗公司 The droxidopa and the pharmaceutical composition thereof that are used for the treatment of fibromyalgia
CN102266563A (en) * 2011-07-13 2011-12-07 赵磊 Compound analgesic composition and preparation method thereof
CN105056133A (en) * 2015-08-21 2015-11-18 孙丕磊 Traditional Chinese medicine pills for treating fibromyalgia syndrome and preparing method of traditional Chinese medicine pills

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678585A (en) * 2002-06-28 2005-10-05 欧洲凯尔特公司 Therapeutic agents useful for treating pain
CN101484152A (en) * 2006-06-08 2009-07-15 舒沃茨药物股份公司 Therapeutic combination for painful medical conditions
CN101657193A (en) * 2007-03-09 2010-02-24 切尔西治疗公司 The droxidopa and the pharmaceutical composition thereof that are used for the treatment of fibromyalgia
CN102266563A (en) * 2011-07-13 2011-12-07 赵磊 Compound analgesic composition and preparation method thereof
CN105056133A (en) * 2015-08-21 2015-11-18 孙丕磊 Traditional Chinese medicine pills for treating fibromyalgia syndrome and preparing method of traditional Chinese medicine pills

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐健: "帕罗西汀和阿米替林治疗原发性纤维肌痛综合征的疗效和安全性对照研究", 《中国心理卫生杂志》 *
高崎: "帕罗西汀与阿米替林治疗原发性纤维肌痛综合征的临床价值分析", 《中国医药指南》 *

Similar Documents

Publication Publication Date Title
CN104523865B (en) Medicine for treating breast diseases
CN102526640B (en) Pantoprazole sodium medicine compound and preparation technology thereof
CN104524247B (en) One treats migrainous medical composition and its use
CN103705789A (en) Pharmaceutical composition for treating cerebral hemorrhage
CN101596302A (en) A kind of treatment treating coronary heart disease and angina pectoris and preparation method thereof
CN103784893B (en) A kind of medicine for the treatment of cerebral apoplexy sequela
CN105944083A (en) Compound nursing agent for treating fibromyalgia syndrome and preparation method of compound nursing agent
CN101244181B (en) Plaster for bone paralysis with function of qufengshengshi, blood circulation activating and stasis removing, and removing the obstruction in the channels to relieve pain, and preparation thereof
CN101518582A (en) Traditional Chinese medicine cream for treating bone fracture diseases and preparation method thereof
CN104474173B (en) A kind of medicine for treating facioplegia
CN102552742B (en) Medicine for treating scapulohumeral periarthritis and rheumatism
US11684631B2 (en) Method of treating cancer with composition of traditional Chinese medicine and its preparation method thereof
CN102319330A (en) Traditional Chinese medicine cataplasma for treating hyperosteogeny and preparation method thereof
CN106581468A (en) Preparation method of traditional Chinese medicine capable of treating gastric ulcer
CN101422489A (en) Traditional Chinese medicine preparation for treating adenocarcinoma
CN105832885A (en) Traditional Chinese medicine composition for treating insomnia
CN104306811B (en) A kind of Chinese medicine composition for treating children's psoriasis vulgaris
CN104740038B (en) One kind treats prostatitic Chinese medicine
CN103251851B (en) Internal and external traditional Chinese medicine formulation for treating rheumatic and rheumatoid diseases
CN102000297B (en) Traditional Chinese medical composition for treating coronary heart disease
CN102940671A (en) Medicine composition for treating diabetic foot
CN101979010A (en) Chinese medicament for treating metrorrhagia
CN101653495A (en) Chinese traditional medicine for curing insomnia
CN106177562A (en) The Chinese medicine composition that a kind for the treatment of is had blood in stool
CN106139032A (en) A kind of Chinese medicine composition treating diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160921